PortfoliosLab logo
Omega Therapeutics, Inc. (OMGA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US68217N1054

CUSIP

68217N105

IPO Date

Jul 30, 2021

Highlights

Market Cap

$7.90M

EPS (TTM)

-$1.32

Total Revenue (TTM)

$4.75M

Gross Profit (TTM)

-$4.59M

EBITDA (TTM)

-$32.39M

Year Range

$0.01 - $2.63

Target Price

$11.50

Short %

26.91%

Short Ratio

6.97

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Omega Therapeutics, Inc.

Popular comparisons:
OMGA vs. CRVO OMGA vs. RXRX
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period


OMGA

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.52%

1M

6.32%

6M

-1.44%

1Y

12.25%

3Y*

12.45%

5Y*

14.20%

10Y*

10.84%

*Annualized

Monthly Returns

The table below presents the monthly returns of OMGA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-34.28%-94.08%179.31%-40.12%-93.50%
202421.26%12.60%-11.19%-38.90%-11.21%4.55%-10.14%-20.97%-17.01%-4.92%-23.88%-15.56%-75.23%
202337.48%-17.71%-6.66%27.03%-0.91%-26.22%-0.18%-34.35%-41.42%-36.28%67.15%31.44%-47.29%
20220.26%4.49%-47.43%-45.35%-33.43%67.40%34.21%-12.35%21.25%-11.25%45.53%-18.43%-49.60%
202113.62%3.69%55.86%-38.43%-37.37%-29.19%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of OMGA is 23, meaning it’s performing worse than 77% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of OMGA is 2323
Overall Rank
The Sharpe Ratio Rank of OMGA is 3232
Sharpe Ratio Rank
The Sortino Ratio Rank of OMGA is 3737
Sortino Ratio Rank
The Omega Ratio Rank of OMGA is 3737
Omega Ratio Rank
The Calmar Ratio Rank of OMGA is 11
Calmar Ratio Rank
The Martin Ratio Rank of OMGA is 77
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Omega Therapeutics, Inc. (OMGA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Omega Therapeutics, Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Omega Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Omega Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Omega Therapeutics, Inc. was 99.97%, occurring on Mar 7, 2025. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.97%Nov 1, 2021840Mar 7, 2025
-23.9%Aug 18, 202125Sep 22, 202123Oct 25, 202148
-3.13%Aug 16, 20211Aug 16, 20211Aug 17, 20212
-1.79%Aug 3, 20211Aug 3, 20214Aug 9, 20215
-0.87%Aug 11, 20211Aug 11, 20211Aug 12, 20212
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Omega Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Omega Therapeutics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -10.4%.


-3.50-3.00-2.50-2.00-1.50-1.00-0.500.002020AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJuly
-0.30
-0.27
Actual
Estimate

Valuation

The Valuation section provides an overview of how Omega Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for OMGA relative to other companies in the Biotechnology industry. Currently, OMGA has a P/S ratio of 1.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for OMGA in comparison with other companies in the Biotechnology industry. Currently, OMGA has a P/B value of 0.2. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items